Citations

Clear

2303 citation(s) found for "Yu, Edward".

Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early‐onset Alzheimer's disease
Nemes, Sára , Logan, Paige E. , Manchella, Mohit K. , Mundada, Nidhi S. , Joie, Renaud La , Polsinelli, Angelina J. , Hammers, Dustin B. , Foroud, Tatiana M., Eloyan, Ani , Dorsant‐Ardón, Valérie , Taurone, Alexander, Thangarajah, Maryanne, Dage, Jeffrey L. , Aisen, Paul , Grinberg, Lea T. , Kramer, Joel H. , Kukull, Walter A. , Rumbaugh, Malia, Soleimani‐Meigooni, David N. , Touroutoglou, Alexandra , Vemuri, Prashanthi , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Stephen , Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S. , Rabinovici, Gil D. , Carrillo, María C. , Apostolova, Liana G. , Vemuri, Prashanthi , Day, Gregory S , La Joie, Renaud , Grinberg, Lea , Rabinovici, Gil D , Wingo, Thomas S , Dage, Jeffrey L , Hammers, Dustin B , Koeppe, Robert A. , Nudelman, Kelly , Iaccarino, Leonardo , Jack, Clifford R. , Murray, Melissa E. , Toga, Arthur W. , Atri, Alireza , Duara, Ranjan , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Musiek, Erik , Womack, Kyle , Wolk, David A. , Dickerson, Bradford Clark

Mayo Clinic

Alzheimer's & Dementia | July 27, 2023 | Volume: 19 | Issue: S9 | Pages: No page available

10.1002/alz.13403 | PMID 37496307 Get It

AbstractINTRODUCTIONWe used sex and apolipoprotein E ε4 (APOE ε4) carrier status as predictors of pathologic burden in early‐onset Alzheimer's disease (EOAD).METHODSWe included baseline data from 77 cognitively normal (CN), 230 EOAD, and 70 EO non‐Alzheimer's disease (EOnonAD) participants from the Longitudinal Early‐Onset Alzheimer's Disease Study (LEADS). We stratified each diagnostic group by males and females, then further subdivided each sex by APOE ε4 carrier status and compared imaging biomarkers in each stratification. Voxel‐wise multiple linear regressions yielded statistical brain maps of gray matter density, amyloid, and tau PET burden.RESULTSEOAD females had greater amyloid and tau PET burdens than males. EOAD female APOE ε4 non‐carriers had greater amyloid PET burdens and greater gray matter atrophy than female ε4 carriers. EOnonAD female ε4 non‐carriers also had greater gray matter atrophy than female ε4 carriers.DISCUSSIONThe effects of sex and APOE ε4 must be considered when studying these populations.HIGHLIGHTS Novel analysis examining the effects of biological sex and apolipoprotein E ε4 (APOE ε4) carrier status on neuroimaging biomarkers among early‐onset Alzheimer's disease (EOAD), early‐onset non‐AD (EOnonAD), and cognitively normal (CN) participants. Female sex is associated with greater pathology burden in the EOAD cohort compared to male sex. The effect of APOE ε4 carrier status on pathology burden was the most impactful in females across all cohorts.
White matter hyperintensities are higher among early‐onset Alzheimer's disease participants than their cognitively normal and early‐onset nonAD peers: Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)
Eloyan, Ani , Thangarajah, Maryanne, An, Na , Borowski, Bret, Reddy, Ashritha L., Aisen, Paul , Dage, Jeffrey L. , Ghetti, Bernardino , Griffin, Percy , Hammers, Dustin B. , Kirby, Kala, Kramer, Joel H. , Kukull, Walter A. , Joie, Renaud La , Mundada, Nidhi S. , Rumbaugh, Malia, Soleimani‐Meigooni, David N. , Touroutoglou, Alexandra , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Rogalskı, Emily , Salloway, Stephen , Sha, Sharon, Turner, Raymond Scott , Wingo, Thomas S. , Gao, Sujuan , Carrillo, María C. , Rabinovici, Gil D. , Apostolova, Liana G. , Dickerson, Brad C., Vemuri, Prashanthi , Borowski, Bret J, Vemuri, Prashanthi , Day, Gregory S , La Joie, Renaud , Rabinovici, Gil D , Ghetti, Bernardino F , Wingo, Thomas S , Dage, Jeffrey L , An, Na, Reddy, Ashritha L., Foroud, Tatiana , Hammers, Dustin B , Iaccarino, Leonardo , Jack, Clifford R. , Kirby, Kala, Koeppe, Robert A. , Murray, Melissa E. , Nudelman, Kelly , Toga, Arthur W. , Atri, Alireza , Duara, Ranjan , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Musiek, Erik , Sha, Sharon J. , Wolk, David A. , Womack, Kyle , Beckett, Laurel

Mayo Clinic

Alzheimer's & Dementia | July 25, 2023 | Volume: 19 | Issue: S9 | Pages: No page available

10.1002/alz.13402 | PMID 37491599 Get It

Abstract INTRODUCTION We compared white matter hyperintensities (WMHs) in early‐onset Alzheimer's disease (EOAD) with cognitively normal (CN) and early‐onset amyloid‐negative cognitively impaired (EOnonAD) groups in the Longitudinal Early‐Onset Alzheimer's Disease Study. METHODS We investigated the role of increased WMH in cognition and amyloid and tau burden. We compared WMH burden of 205 EOAD, 68 EOnonAD, and 89 CN participants in lobar regions using t ‐tests and analyses of covariance. Linear regression analyses were used to investigate the association between WMH and cognitive impairment and that between amyloid and tau burden. RESULTS EOAD showed greater WMHs compared with CN and EOnonAD participants across all regions with no significant differences between CN and EOnonAD groups. Greater WMHs were associated with worse cognition. Tau burden was positively associated with WMH burden in the EOAD group. DISCUSSION EOAD consistently showed higher WMH volumes. Overall, greater WMHs were associated with worse cognition and higher tau burden in EOAD. Highlights This study represents a comprehensive characterization of WMHs in sporadic EOAD. WMH volumes are associated with tau burden from positron emission tomography (PET) in EOAD, suggesting WMHs are correlated with increasing burden of AD. Greater WMH volumes are associated with worse performance on global cognitive tests. EOAD participants have higher WMH volumes compared with CN and early‐onset amyloid‐negative cognitively impaired (EOnonAD) groups across all brain regions.
Cerebrospinal fluid biomarkers in the Longitudinal Early‐onset Alzheimer's Disease Study
Dage, Jeffrey L. , Eloyan, Ani , Thangarajah, Maryanne, Hammers, Dustin B. , Fagan, Anne M. , Gray, Julia, Snoddy, Casey, Faber, Kelley , Foroud, Tatiana M., Aisen, Paul , Griffin, Percy , Grinberg, Lea T. , Kirby, Kala, Kramer, Joel H. , Kukull, Walter A. , Joie, Renaud La , Mundada, Nidhi S. , Rumbaugh, Malia, Soleimani‐Meigooni, David N. , Touroutoglou, Alexandra , Vemuri, Prashanthi , Day, Gregory S. , Graff‐Radford, Neill R. , Duara, Ranjan , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Stephen , Sha, Sharon J. , Turner, Raymond Scott , Wingo, Thomas S. , Carrillo, María C. , Rabinovici, Gil D. , Apostolova, Liana G. , Vemuri, Prashanthi , Day, Gregory S , La Joie, Renaud , Grinberg, Lea , Rabinovici, Gil D , Wingo, Thomas S , Dage, Jeffrey L , Hammers, Dustin B , Schindler, Suzanne E. , Nudelman, Kelly , Iaccarino, Leonardo , Kirby, Kala, Koeppe, Robert A. , Murray, Melissa E. , Toga, Arthur W. , Atri, Alireza , Beckett, Laurel , Duara, Ranjan , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Musiek, Erik , Wolk, David A. , Womack, Kyle , Dickerson, Bradford Clark

Mayo Clinic

Alzheimer's & Dementia | July 25, 2023 | Volume: 19 | Issue: S9 | Pages: No page available

10.1002/alz.13399 | PMID 37491668 Get It

AbstractIntroductionOne goal of the Longitudinal Early Onset Alzheimer's Disease Study (LEADS) is to define the fluid biomarker characteristics of early‐onset Alzheimer's disease (EOAD).MethodsCerebrospinal fluid (CSF) concentrations of Aβ1‐40, Aβ1‐42, total tau (tTau), pTau181, VILIP‐1, SNAP‐25, neurogranin (Ng), neurofilament light chain (NfL), and YKL‐40 were measured by immunoassay in 165 LEADS participants. The associations of biomarker concentrations with diagnostic group and standard cognitive tests were evaluated.ResultsBiomarkers were correlated with one another. Levels of CSF Aβ42/40, pTau181, tTau, SNAP‐25, and Ng in EOAD differed significantly from cognitively normal and early‐onset non‐AD dementia; NfL, YKL‐40, and VILIP‐1 did not. Across groups, all biomarkers except SNAP‐25 were correlated with cognition. Within the EOAD group, Aβ42/40, NfL, Ng, and SNAP‐25 were correlated with at least one cognitive measure.DiscussionThis study provides a comprehensive analysis of CSF biomarkers in sporadic EOAD that can inform EOAD clinical trial design.
COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases: results from the COVAD study
Andréoli, Laura , Lini, Daniele , Schreiber, Karen , Parodis, Ioannis , Sen, Parikshit , Ravichandran, Naveen , Day, Jessica , Joshi, Mrudula , Jagtap, Kshitij , Nune, Arvind , Nikiphorou, Elena , Tan, Ai Lyn , Velikova, Tsvetelina , Milchert, Marcin , Gracia‐Ramos, Abraham Edgar , Kuwana, Masataka , Patel, Aarat , Pauling, John D , Wincup, Chris , Tehozol, Erick Adrian Zamora , Colunga-Pedraza, I. J. , Chibuzo, Okwara Celestine , Katchamart, Wanruchada , Goo, Phonpen Akarawatcharangura , Shumnalieva, Russka , Kibbi, Lina El , Vaidya, Binit , Shaharir, Syahrul Sazliyana , Hasan, A T M Tanveer , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Salim, Babur , Gheita, Tamer A. , Chinoy, Hector , Agarwal, Vikas , Gupta, Latika, Group, COVAD Study, Kardeş, Sinan , Vince, Melinda Nagy, Singh, Yogesh Preet , Ranjan, Rajiv , Jain, Avinash , Pandya, Sapan C , Sharma, Aman , Manoj, Manesh , Gupta, Vikas , Patro, Pradeepta Sekhar , Ajmani, Sajal , Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Bommakanti, Keerthi Talari, Shukla, Anuj , Ghodke, Akanksha, Fazal, Zoha Zahid , Yıldırım, Reşit, Sambataro, Gianluca , Atzeni, Fabiola , Parisi, Simone , Bocci, Elena Bartoloni, Sainaghi, Pier Paolo , Orsolini, Giovanni , Angelis, Rossella De , Danieli, Maria Giovanna , Giollo, Alessandro, Loarce‐Martos, Jesus , Prieto‐González, Sergio , Nakashima, Ran , Sato, Shinji, Kaneko, Yuko , Tomaras, Stylianos, Aharonov, Or, bouchti, Imane El, Baba, Zineb, Maurier, François, Meyer, Alain, Limaye, Vidya, Hudson, Marie , Landon‐Cardinal, Océane , Zuleta, Wilmer Gerardo Rojas, Cajas, Javier, Silva, José António Pereira, Doskaliuk, Bohdana , Ima-Edomwonyi, Uyi, Dedeke, Ibukunoluwa, Madu, Nwankwo Henry, Yerima, Abubakar , Olaosebikan, Hakeem , Becky, A, Koussougbo, Oruma Devi, Palalane, Elisa, Chinchay, Lyn , Bernaola, José Proaño, Pimentel, Victorio, Fathi, Hanan Mohammed, Harifi, Ghita , Fuentes-Silva, Yurilís , Cabriza, Karoll, Losanto, Jonathan, Colaman, Nelly, Cachafeiro-Vilar, Antonio , Bautista, Generoso Guerra , Ho, Enrique Julio Giraldo, Nunez, Lilith Stange, Vergara, M Cristian, Báez, Jossiell Then , Alonzo, Hugo, Pastelin, Carlos Benito Santiago, Obiols, Alejandro Quiñónez, Chávez, Nilmo , Ordóñez, Andrea Bran , Llerena, Gil Alberto Reyes, Sierra-Zorita, Radames, Arrieta, Dina , Hidalgo, Eduardo Romero, Saénz, Ricardo, Escalante, M Idania, Calapaqui, Wendy, Quezada, Ivonne, Arredondo, Gabriela, Giollo, Alessandro , Gupta, Latika , Agarwal, Vishwesh , Saha, Sreoshy , Tan, Ai Lyn , Shinjo, Samuel Katsuyuki , Ziade, Nelly , Velikova, Tsvetelina , Milchert, Marcin , Gracia-Ramos, Abraham Edgar , Cavagna, Lorenzo , Kuwana, Masataka , Knitza, Johannes , Makol, Ashima , Pauling, John D , Wincup, Chris , Zamora Tehozol, Erick Adrian , Rojas Serrano, Jorge , García-De La Torre, Ignacio , Colunga-Pedraza, Iris J , Merayo-Chalico, Javier , Katchamart, Wanruchada , Shumnalieva, Russka , Chen, Yi-Ming , Hoff, Leonardo Santos , El Kibbi, Lina , Halabi, Hussein , Vaidya, Binit , Sazliyana Shaharir, Syahrul , Hasan, A T M Tanveer , Gutiérrez, Carlos Enrique Toro , Lilleker, James B , Salim, Babur , Gheita, Tamer , Chatterjee, Tulika , Saavedra, Miguel A , Distler, Oliver , Chinoy, Hector , Agarwal, Vikas , Aggarwal, Rohit , Gupta, Latika , Joshi, Mrudula , Day, Jessica , Parodis, Ioannis , Nune, Arvind , Naveen, R , Agarwal, Vikas , Dey, Dzifa , Caballero-Uribe, Carlo Vinicio , Sen, Parikshit , Andreoli, Laura , Jagtap, Kshitij , De Angelis, Rossella , Singh, Yogesh Preet , Agarwal, Vishwesh , Saha, Sreoshy , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Makol, Ashima , Barman, Bhupen , Torre, Ignacio García‐De La , Goo, Phonpen Akawatcharangura , Chen, Yi‐Ming , Halabi, Hussein , Chatterjee, Tulika , Distler, Oliver , Aggarwal, Rohit , Group, COVAD Study, Griger, Zoltán , Pilania, Rakesh Kumar , Kavadichanda, Chengappa G. , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Asranna, Ajay , Pande, Arun K. , Chandwar, Kunal , Boro, Hiya , Cansu, Döndü Üsküdar , Gasparyan, Armen Yuri , Papa, Nicoletta Del , Govoni, Marcello , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Venerito, Vincenzo , Grignaschi, Silvia , Alunno, Alessia , Iannone, Florenzo , Fornaro, Marco , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Gonzalez, Raquel Aranega, Yoshida, Akira, Kimura, Naoki, Gono, Takahisa , Tomaras, Stylianos , Proft, Fabian Nikolai , Holzer, Marie‐Therese , Gromova, Margarita Aleksandrovna , Hmamouchi, Ihsane , Giannini, Margherita , Maurier, F. , Campagne, Julien , Meyer, Alain , Langguth, Daman , Limaye, Vidya , Needham, Merrilee , Srivastav, Nilesh , Arbeláez-Cortés, Álvaro , Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena , Ima-Edomwonyi, Uyi, Emorinken, Airenakho , So, Ho , Ugarte‐Gil, Manuel F. , Mohammed, Reem Hamdy A , Salinas, Rodrigo Nicolás Garcia

Mayo Clinic

Rheumatology | July 25, 2023 | Volume: 63 | Issue: 5 | Pages: 1341-1351

10.1093/rheumatology/kead382 | PMID 37505460 Get It

Abstract Objectives We investigated coronavirus disease 2019 (COVID-19) vaccine safety in pregnant and breastfeeding women with autoimmune diseases (AID) in the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. Methods Delayed-onset (>7 days) vaccine-related adverse events (AE), disease flares and AID-related treatment modifications were analysed upon diagnosis of AID vs healthy controls (HC) and the pregnancy/breastfeeding status at the time of at least one dose of vaccine. Results Among the 9201 participants to the self-administered online survey, 6787 (73.8%) were women. Forty pregnant and 52 breastfeeding patients with AID were identified, of whom the majority had received at least one dose of COVID-19 vaccine (100% and 96.2%, respectively). AE were reported significantly more frequently in pregnant than in non-pregnant patients (overall AE 45% vs 26%, P = 0.01; minor AE 40% vs 25.9%, P = 0.03; major AE 17.5% vs 4.6%, P < 0.01), but no difference was found in comparison with pregnant HC. No difference was observed between breastfeeding patients and HC with respect to AE. Post-vaccination disease flares were reported by 17.5% of pregnant and 20% of breastfeeding patients, and by 18.3% of age- and disease-matched non-pregnant and non-breastfeeding patients (n = 262). All pregnant/breastfeeding patients who experienced a disease flare were managed with glucocorticoids; 28.6% and 20% of them required initiation or change in immunosuppressants, respectively. Conclusion This study provides reassuring insights into the safety of COVID-19 vaccines administered to women with AID during the gestational and post-partum periods, helping overcome hesitant attitudes, as the benefits for the mother and for the fetus by passive immunization appear to outweigh potential risks.
Dietary Patterns Are Not Associated With Disease Activity Among Patients With Inflammatory Conditions of the Pouch in a Prospective Cohort
Barnes, Edward L. , Beniwal‐Patel, Poonam , Deepak, Parakkal , Raffals, Laura H., Kayal, Maia , Dubinsky, Marla C. , Chang, Shannon, Higgins, Peter , Barr, Jennifer I, Anderson, Chelsea , Long, Millie D. , Herfarth, Hans , Herfarth, Hans H , Kayal, Maia , Deepak, Parakkal , Barnes, Edward L , Cross, Raymond K.

Mayo Clinic

Crohn's & Colitis 360 | July 19, 2023 | Volume: 5 | Issue: 3 | Pages: No page available

10.1093/crocol/otad039 | PMID 37519405 Get It

Abstract Background Evidence-based recommendations regarding the influence of diet on inflammatory conditions of the pouch after restorative proctocolectomy with ileal pouch–anal anastomosis (IPAA) are limited. Methods We analyzed dietary patterns at enrollment in a prospective registry of patients with 1 of 4 inflammatory conditions of the pouch (acute pouchitis, chronic antibiotic-dependent pouchitis, chronic antibiotic refractory pouchitis, and Crohn’s disease of the pouch). We analyzed dietary intake by disease activity at enrollment and then compared dietary patterns among patients who remained in remission throughout the 12-month follow-up to those patients who experienced a disease relapse. We also compared dietary patterns among patients with inflammatory conditions of the pouch to the United States Department of Agriculture (USDA) recommended daily goals. Results Among 308 patients, there were no differences in dietary patterns among patients with 1 of the 4 disease states at enrollment. Additionally, among the 102 patients in remission at baseline, there were no significant differences noted among patients who went on to experience a disease flare in the 12 months after enrollment compared to those patients who remained in remission. However, patients with inflammatory conditions of the pouch demonstrated decreased intake of several food groups and macronutrients including dairy, fruits, vegetables, whole grains, and fiber when compared to USDA recommendations. Conclusions In a prospective cohort, we demonstrated no impact of dietary patterns on disease activity. The relative deficiencies in several food groups and macronutrients among patients after IPAA indicate the potential role of targeted nutritional counseling in this population.
Arrhythmic mitral valve prolapse and mitral annular disjunction: pathophysiology, risk stratification, and management
Essayagh, Benjamin , Sabbag, Avi , El‐Am, Edward , Cavalcante, João L. , Michelena, Héctor I. , Enriquez‐Sarano, Maurice , Michelena, Hector I , Enriquez-Sarano, Maurice , El-Am, Edward , Essayagh, Benjamin , Sabbag, Avi

Mayo Clinic

European Heart Journal | July 19, 2023 | Volume: 44 | Issue: 33 | Pages: 3121-3135

10.1093/eurheartj/ehad491 | PMID 37561995 Get It

Abstract Mitral valve prolapse (MVP) is the most frequent valve condition but remains a conundrum in many aspects, particularly in regard to the existence and frequency of an arrhythmic form (AMVP) and its link to sudden cardiac death. Furthermore, the presence, frequency, and significance of the anatomic functional feature called mitral annular disjunction (MAD) have remained widely disputed. Recent case series and cohorts have shattered the concept that MVP is most generally benign and have emphasized the various phenotypes associated with clinically significant ventricular arrhythmias, including AMVP. The definition, evaluation, follow-up, and management of AMVP represent the focus of the present review, strengthened by recent coherent studies defining an arrhythmic MVP phenotypic that would affect a small subset of patients with MVP at concentrated high risk. The role of MAD in this context is of particular importance, and this review highlights the characteristics of AMVP phenotypes and MAD, their clinical, multimodality imaging, and rhythmic evaluation. These seminal facts lead to proposing a risk stratification clinical pathway with consideration of medical, rhythmologic, and surgical management and have been objects of recent expert consensus statements and of proposals for new research directions.
Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delay
Coelho, Teresa , Grogan, Martha , Conceição, Isabel , Kristen, Arnt V. , Wixner, Jonas , González‐Moreno, Juan , Maurer, Mathew S. , García‐Pavía, Pablo , Tournev, Ivailo , González‐Costello, José , Cariou, Eve, Glass, Oliver, Chapman, Doug, Amass, Leslie, investigators, on behalf of the THAOS, Hüsing‐Kabar, Anna, Drachman, Brian, Sekijima, Yoshiki , Jeon, Eun‐Seok , Slosky, David, Hanna, Mazen , Freimer, Miriam , Muñoz-Beamud, Francisco, Mølgaard, Henning, Press, Rayomand , Cirami, Calogero Lino , Plana, Josep Maria Campistol, Inamo, Jocelyn , Quan, Dianna , Dori, Amir , Murali, Srinivas, Živković, Saša , Correia, Edileide de Barros , Nicolau, José Nativi, Tallaj, José , Fernández‐Torrón, Roberto , Polydefkis, Michael , Tauras, James M. , Ventura, Hector, Brunkhorst, Robert, Darstein, Felix , Marburger, Tessa, Mueller, Christopher R. , Cleemput, Johan Van , Parman, Yeşim , Sarswat, N., Warner, Alberta L. , Steidley, D. Eric , Ralph, Jeffrey , Cotts, William, Hoffman, James E. , Rugiero, Marcelo, Misawa, Sonoko , Muñoz-Blanco, José Luís , Dávila, Lucía Galán, Sadeh, Menachem , Luo, Jin, Kyriakides, Theodoros , Wang, Annabel , Dispenzieri, Angela , Conceição, Isabel , Garcia-Pavia, Pablo , Dispenzieri, Angela , Waddington‐Cruz, Márcia , Diemberger, Igor , Maurer, Mathew S , Planté‐Bordeneuve, Violaine , González-Duarte, Alejandra , investigators, on behalf of the THAOS, Barroso, Fábio , Ueda, Mitsuharu , Mazzeo, Anna Teresa , Gentile, Luca , Luigetti, Marco , Adams, David , Nienhuis, Hans L. A. , Emdin, Michele , Miller, Edward J. , Hummel, Scott L. , Witteles, Ronald , Shah, Sanjiv J , Lenihan, Daniel , Azevedo, Olga , Tan, Cheng‐Yin , Fine, Nowell Mark , Tschöpe, Carsten , Obici, Laura , BADELITA, Sorina Nicoleta , Gottlieb, Stephen S. , Oh, Jeeyoung , Mueller, Christopher, Salutto, Valeria , Chao, Chi‐Chao , Kaufmann, Horacio

Mayo Clinic

Amyloid | July 17, 2023 | Volume: 30 | Issue: 4 | Pages: 445-448

10.1080/13506129.2023.2229484 | PMID 37459334 Get It

Network Connectivity Alterations across the MAPT Mutation Clinical Spectrum
Zhang, Liwen , Flagan, Taru , Häkkinen, Suvi , Chu, Stephanie A. , Brown, Jesse A. , Lee, Alex J. , Mandelli, Maria Luisa , Gorno‐Tempini, Maria Luisa , Sturm, Virginia E. , Yokoyama, Jennifer S. , Domoto‐Reilly, Kimiko , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Huey, Edward D. , Kantarci, Kejal , Lago, Argentina Lario , Mackenzie, Ian R. , Mendez, Mario F. , Onyike, Chiadi U. , Ramos, Eliana Marisa , Roberson, Erik D. , Weıntraub, Sandra , Forsberg, Leah K. , Heuer, Hilary W. , Boxer, Adam L. , Rosen, Howard J. , Lee, Suzee E. , Consortia, the ARTFL/LEFFTDS/ALLFTD, Kantarci, Kejal , Tartaglia, Maria Carmela , Lee, Suzee E , Roberson, Erik , Yokoyama, Jennifer , Domoto-Reilly, Kimiko , Pasquini, Lorenzo , Appleby, Brian S. , Cobigo, Yann , Dickerson, Bradford Clark , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Litvan, Irene , Toga, Arthur W. , Wszołek, Zbigniew K. , Boeve, Bradley F. , Miller, Bruce L. , Seeley, William W. , Consortia, the ARTFL/LEFFTDS/ALLFTD

Mayo Clinic

Annals of Neurology | July 11, 2023 | Volume: 94 | Issue: 4 | Pages: 632-646

10.1002/ana.26738 | PMID 37431188 Get It

ObjectiveMicrotubule‐associated protein tau (MAPT) mutations cause frontotemporal lobar degeneration, and novel biomarkers are urgently needed for early disease detection. We used task‐free functional magnetic resonance imaging (fMRI) mapping, a promising biomarker, to analyze network connectivity in symptomatic and presymptomatic MAPT mutation carriers.MethodsWe compared cross‐sectional fMRI data between 17 symptomatic and 39 presymptomatic carriers and 81 controls with (1) seed‐based analyses to examine connectivity within networks associated with the 4 most common MAPT‐associated clinical syndromes (ie, salience, corticobasal syndrome, progressive supranuclear palsy syndrome, and default mode networks) and (2) whole‐brain connectivity analyses. We applied K‐means clustering to explore connectivity heterogeneity in presymptomatic carriers at baseline. Neuropsychological measures, plasma neurofilament light chain, and gray matter volume were compared at baseline and longitudinally between the presymptomatic subgroups defined by their baseline whole‐brain connectivity profiles.ResultsSymptomatic and presymptomatic carriers had connectivity disruptions within MAPT‐syndromic networks. Compared to controls, presymptomatic carriers showed regions of connectivity alterations with age. Two presymptomatic subgroups were identified by clustering analysis, exhibiting predominantly either whole‐brain hypoconnectivity or hyperconnectivity at baseline. At baseline, these two presymptomatic subgroups did not differ in neuropsychological measures, although the hypoconnectivity subgroup had greater plasma neurofilament light chain levels than controls. Longitudinally, both subgroups showed visual memory decline (vs controls), yet the subgroup with baseline hypoconnectivity also had worsening verbal memory and neuropsychiatric symptoms, and extensive bilateral mesial temporal gray matter decline.InterpretationNetwork connectivity alterations arise as early as the presymptomatic phase. Future studies will determine whether presymptomatic carriers' baseline connectivity profiles predict symptomatic conversion. ANN NEUROL 2023;94:632–646
A RE-AIM Analysis of a Mental Health App for Undergraduate and Medical Students during the COVID-19 Pandemic: A Retrospective Cross-Sectional Study
Berreta, Krisdaniel, Nguyen, Cynthia , Stoner, Alexis M. , Ridgeway, Lindsey M, Wilson, Angela , Fadel, Natalie , Nguyen, Cynthia, Biber, Duke

Mayo Clinic

International Journal of Environmental Research and Public Health | July 3, 2023 | Volume: 20 | Issue: 13 | Pages: 6266

10.3390/ijerph20136266 | PMID 37444113 Get It

Objective: The purpose of this study was to use the RE-AIM framework to evaluate the implementation of a mental health app designed for undergraduate and medical students during the COVID-19 pandemic. Participants: Medical (n = 270) and undergraduate students (n = 1386) from five universities in the Appalachian region in the United States participated in this study. Methods: Universities from the United States were recruited to deploy the Sharpen app for medical and undergraduate students. The Sharpen app provided psychoeducational modules in mental health literacy, social-emotional learning, mindfulness-based stress reduction, and suicide prevention to promote protective factors for students. The utilization of the Sharpen app was analyzed using the RE-AIM framework using a retrospective, cross-sectional design. Results: Reach: A total of 12.72% of medical students and 6.00% of undergraduate students participated in the study. Efficacy: Medical students viewed significantly more pages, had a significantly higher unique page view average, and a statistically significant exit percentage when compared to undergraduate students. Adoption: A total of 100% of the universities that were recruited participated in the study. Implementation: Five out of six implementation criteria were included, indicating high implementation. Maintenance: All of the universities continued using the Sharpen app following the end of data collection, resulting in a 100% maintenance rate. Conclusions: The RE-AIM framework indicated usability and maintenance by medical and undergraduate students. Future research needs to implement a more rigorous design to determine the impact of the Sharpen app on mental health outcomes in medical and undergraduate students.
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
Gertz, Morie A. , Cohen, Adam D. , Comenzo, Raymond L. , Landau, Heather , Libby, Edward N., Liedtke, Michaela , Sanchorawala, Vaishali , Wechalekar, Ashutosh , Zonder, Jeffrey A. , Walling, Jackie , Guthrie, Spencer , Nie, Christie, Karp, Carol L. , Kinney, Gene G. , Kastritis, Efstathios , Landau, Heather , Liedtke, Michaela , Sanchorawala, Vaishali , Palladini, Giovanni , Merlini, Giampaolo , Gertz, Morie A , Cohen, Adam D , Kastritis, Efstathios , Schönland, Stefan , Wechalekar, Ashutosh D. , Palladini, Giovanni , Karp, Carol, Jin, Yuying, Merlini, Giampaolo

Mayo Clinic

Blood | June 27, 2023 | Volume: 142 | Issue: 14 | Pages: 1208-1218

10.1182/blood.2022019406 | PMID 37366170 Get It

Abstract Amyloid light-chain (AL) amyloidosis is a rare, typically fatal disease characterized by the accumulation of misfolded immunoglobulin light chains (LCs). Birtamimab is an investigational humanized monoclonal antibody designed to neutralize toxic LC aggregates and deplete insoluble organ-deposited amyloid via macrophage-induced phagocytosis. VITAL was a phase 3 randomized, double-blind, placebo-controlled clinical trial assessing the efficacy and safety of birtamimab + standard of care (SOC) in 260 newly diagnosed, treatment-naive patients with AL amyloidosis. Patients received 24 mg/kg IV birtamimab + SOC or placebo + SOC every 28 days. The primary composite end point was the time to all-cause mortality (ACM) or centrally adjudicated cardiac hospitalization ≥91 days after the first study drug infusion. The trial was terminated early after an interim futility analysis; there was no significant difference in the primary composite end point (hazard ratio [HR], 0.826; 95% confidence interval [CI], 0.574-1.189; log-rank P = .303). A post hoc analysis of patients with Mayo stage IV AL amyloidosis, those at the highest risk of early mortality, showed significant improvement in the time to ACM with birtamimab at month 9 (HR, 0.413; 95% CI, 0.191-0.895; log-rank P = .021). At month 9, 74% of patients with Mayo stage IV AL amyloidosis treated with birtamimab and 49% of those given placebo survived. Overall, the rates of treatment-emergent adverse events (TEAEs) and serious TEAEs were generally similar between treatment arms. A confirmatory phase 3 randomized, double-blind, placebo-controlled clinical trial of birtamimab in patients with Mayo stage IV AL amyloidosis (AFFIRM-AL; NCT04973137) is currently enrolling. The VITAL trial was registered at www.clinicaltrials.gov as #NCT02312206.